(PharmaNewsWire.Com, February 24, 2018 ) Dry eyes are a condition that is becoming progressively more well-known and suffered from around the world. Dry eye disease is also known as Keratoconjuctivitis Sicca is a common phenomenon, which is estimated to have a prevalence of 8% to 34% across the globe. Considering this, numerous key players are investing on the development of new treatments for dry eye disease which is projected to drive the expansion of the global market for dry eye disease market. Market Research Hub (MRH) has announced the inclusion of a fresh study titled “Dry Eye Disease Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017 – 2025” to its massive database, which offers a crystal clear overview of market covering market dynamics such as factors, restraints, and opportunities present in the global market.
In the initial section, the study describes the scope of the analysis along with the current market overview of dry eye disease. Dry eye disease is a multifactorial disease which is characterized by an insufficiency of tears in the eye. It has been analyzed that raising awareness among patients and surging healthcare expenditures have created an environment conducive to the market’s growth. As per the study key findings, the dry eye disease market will expand at a CAGR of 4.5% over the forecast period between 2017 and 2025. Increasing at this pace, the market, which had a valuation of US$ 5,045.2 Mn in 2016 in terms of revenue, is projected to rise to US$ 7,780.0 Mn by 2025.
North America to Display Significant Growth Opportunities
Geographically, prime regions emphasized in the study are North America, Europe, Latin America Asia Pacific, Middle East & Africa (MEA), these are analyzed in terms of market revenue. As per the report, North America arisen as the largest market for dry eye disease globally on the back of the presence of a sophisticated healthcare infrastructure.
Moving further, the global dry eye disease market has been segmented on the basis of product type and distribution channel. On the basis of product, anti-inflammatory drugs segment is projected to lead the market in terms of revenue and continues to dominate the market till 2025, followed by artificial tears segment. Also, the introduction of new anti-inflammatory drugs such as Lifitegrast (Xiidra) and advancements in the existing cyclosporine eye drops is estimated to propel expansion of this segment.
Competitive Scenario
The final section of the report deals with the competitive landscape which outlines the key players that are operating in the dry eye disease market along with details such as business positioning, financial standing, and SWOTs. Key players mentioned in the study are Valeant Pharmaceuticals International, Inc., Santen Pharmaceutical Co., Ltd., Sentiss Pharma Pvt. Ltd., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Senju Pharmaceutical Co., Ltd., Mitotech S.A., Allergan plc, Shire plc, TRB Chemedica International SA, Sun Pharmaceutical Industries Ltd., Johnson & Johnson, and FCI S.A.S.
Market Research Hub (MRH) is a next-generation reseller of research reports of different sector like pharmaceutical manufacturing industry reports and analysis. MRH’s expansive collection of industry reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
